Objective: This study aimed to evaluate the value of the flexible fasting (FF) technology in helping hypertension improvement in patients with essential hypertension and obesity.
Method:We recruited and ultimately selected 86 volunteers with essential hypertension and obesity in this study as a quasi experiment. The volunteers went through three phases, namely, the baseline anti-hypertensive therapy stage (Phase-1), the FF intervention stage (Phase-2), the normal diet recovery stage (Phase-3), each for seven days. During the Phase-2, all subjects fasted and began to substitute the FF food for conventional food. Patients' systolic/diastolic blood pressure (abbreviated as SBP/DBP), body mass index (BMI) and body weight were monitored in details each day. The trial data of all subjects were statistically analyzed using self-controlled designs.Result: After the FF intervention, the subjects' blood pressure, body mass and BMI all showed naturally decreases by comparison to that before the intervention. The remarkable decreases in SBP/DBP, Body Mass and BMI were observed in Phase-3 after FF intervention when compared to Phase-1 [SBP: (115.2±8.492) vs (121.2±13.72) mmHg, q=34.14, P<0.001]; [DBP: (76.03±5.37) vs (78.36±7.094) mmHg, q=10.96, P<0.05)]; [Body Mass: (68.86±13.04) vs (73.11±13.49)kg, q=61.56, P<0.0001]; [BMI: (25.42±3.359) vs (27.03±3.45) kg/m 2 , q=100, P<0.0001]. All patients did not experience any discomfort or symptoms during the trial.
Conclusion:The FF technology is an effective approach to improve hypertension.